SSTR2 and breast carcinoma: Cescato et al. performed in vitro autoradiography on several sstr2-positive primary tumor samples, including breast carcinomas, and suggested that the antagonist 177Lu-DOTA-BASS bound to more sites on the tumor samples than the agonist 177Lu-DOTATATE (Cescato et al. 2011).